PLG and neoplasm: The plasminogen activation system, comprising the urokinase‐type plasminogen activator (uPA), the cellular receptor for uPA (uPAR), and its specific inhibitor plasminogen activator inhibitor‐1 (PAI‐1 or SERPINE1), is recognized to play a vital role in tumor progression and angiogenesis [15, 16].